ULLA LAAKSO: Open Payments
NPI 1598841371 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$181,632 in 547 payments from 20 companies in 2025. Trend: 2023 $172,345 · 2024 $168,227 · 2025 $181,632
Speaker / faculty: $106,568Honoraria: $26,850Travel & lodging: $20,803Consulting: $14,398Food & beverage: $12,902Education: $111
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 74 | $49,071 |
| Alkermes, Inc. | 55 | $28,440 |
| Otsuka America Pharmaceutical, Inc. | 31 | $19,811 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $19,802 |
| E.R. Squibb & Sons, L.L.C. | 63 | $19,480 |
| Axsome Therapeutics, Inc. | 41 | $14,552 |
| Supernus Pharmaceuticals, Inc. | 21 | $11,572 |
| ABBVIE INC. | 40 | $8,269 |
| Tris Pharma Inc | 44 | $7,682 |
| Lundbeck LLC | 47 | $897 |
Products named: FANAPT, LYBALVI, CAPLYTA, COBENFY, Auvelity, ABILIFY MAINTENA, Qelbree, VRAYLAR.
Industry payments across NY — which companies pay providers there.
